Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3383083 | 0.95 | SETD7 (0.35) | SETD7CHRNB4CHRNA3ADORA3AR | |
| Trifluoroacetic Acid SCHEMBL3382424 | 0.85 | KDM1A (0.36) | — | |
| SCHEMBL3383406 | 0.81 | SETD7 (0.40) | SETD7CHRNB4CHRNA3 | |
| SCHEMBL3380020 | 0.80 | SETD7 (0.35) | SETD7 | |
| SCHEMBL13617538 | 0.80 | SETD7 (0.35) | SETD7 | |
| SCHEMBL3381668 | 0.80 | SETD7 (0.35) | SETD7CHRNB4CHRNA3 | |
| SCHEMBL4669628 | 0.79 | SETD7 (0.46) | SETD7 | |
| SCHEMBL3384341 | 0.78 | CHRNA7 (0.36) | SETD7 | |
| SCHEMBL3379158 | 0.78 | SETD7 (0.42) | SETD7CHRNB4CHRNA3 | |
| SCHEMBL3382259 | 0.77 | TRPA1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896467-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138528-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | SETD7 4281/4885CHRNB4 190/4885CHRNA3 86/4885 |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | SETD7 4281/4885CHRNB4 190/4885CHRNA3 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.